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Imaging Vascular Nicotine Receptors
A New Window Onto Vascular Disease*
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rIn the past 20 years, it has become increasingly
apparent that nicotinic acetylcholine receptors
(nAChRs) exist outside of the nervous system and
neuromuscular junction (1,2). These non-neuronal
nAChRs play important roles in modulating the
immune cell activation (3), keratinocyte prolifera-
tion and migration (4), and airway and bladder
epithelial function (5,6), as well as the adult and
embryonic stem cell behavior and fate (7–9). Fur-
thermore, nAChRs expressed by tumor cells play a
role in the progression of malignancy (10).
See page 528
The nAChRs also exist in the vasculature, to-
gether with the entire cholinergic machinery for
synthesis, storage, and metabolism of acetylcholine
(ACh). Choline acetyltransferase in the endothe-
lium generates ACh from acetyl coenzyme A and
choline (11). A high-affinity choline receptor is
expressed by endothelial and vascular smooth mus-
cle cells (12), providing the substrate for ACh
synthesis. Vascular ACh is degraded by acetylcho-
linesterase and butyrylcholinesterases (13,14) in the
vessel wall, thereby limiting the cholinergic effect in
time and space.
Endogenous ACh produced in the vessel wall, or
exogenous nicotine, therefore stimulates vascular
nAChRs. Stimulation of the vascular nAChR has a
trophic effect on the endothelium and vascular
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urvival (15,16) and releasing vasoactive and growth
actors (e.g., nitric oxide and fibroblast growth
actor) that maintain vascular homeostasis and vas-
ular repair. However, under certain circumstances
e.g., tobacco exposure), excessive stimulation of
hese vascular receptors may contribute to patho-
ogical angiogenesis, such as that involved in ath-
rosclerotic plaque neovascularization, tumor pro-
ression, and age-related macular degeneration
17–19). Accordingly, methods to characterize the
xpression and activity of vascular nAChRs in
ealth and disease may be useful.
The paper by Bucerius et al. (20) in this issue
f iJACC describes their novel application of an
maging agent to visualize vascular nAChRs in
umans. The agent, 2-18F-Fluoro-3-[2(S)-2-
zetidinylmethoxy]pyridine ([18F]-2-Fluoro-
85380) had previously been used with positron
mission tomography (PET) imaging to detect
AChRs in the brain, specifically those containing
2 subunits. These previous studies have provided
vidence for dysregulation of neuronal nAChRs in
atients with Parkinson’s disease (PD) in whom
here seems to be a reduction in the [18F]-2-
luoro-A85380 signal (21). This finding is consis-
ent with prior histopathologic studies showing a
eduction of 2-containing receptors in the brains
f patients with PD (22). By contrast, smokers have
greater density of neuronal 42 receptors, as
ssessed by PET imaging using this probe (23).
In the current investigation, a small number of
ealthy volunteers or patients with PD or multiple
ystem atrophy underwent PET/computed tomog-
aphy scanning after intravenous administration of
18F]-2-Fluoro-A85380 (20). Subsequently, the ca-
otids, ascending aorta, aortic arch, and descending
orta were assessed by using a standardized image
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538analysis protocol. Four different parameters were
developed to quantitate vascular uptake of the
probe. How well these different parameters agreed
with each other was not assessed, but generally
speaking, the conclusions drawn would be similar
no matter which parameter was used.
Most significantly, there was uptake of the probe
into the vessel wall in all subjects (20). This finding
suggests, but does not prove, that there are 2-
ontaining vascular nAChRs in each of these terri-
ories. It would be more convincing if the investi-
ators could document that administration of an
nlabeled agonist (e.g., nicotine) could compete
ith the probe for binding sites on vascular
AChRs (i.e., that the unlabeled agonist could
ttenuate the signal). Even so, this observation
ould not prove that the probe was detecting
ascular nAChRs because it might rather be detect-
ng infiltrating cells expressing nAChRs. Specifi-
ally, it is known that immune cells express
AChRs (3), and the probe might be detecting
nfiltrating macrophages in the vessel wall. Accord-
ngly, it would be more convincing if there was
istopathologic support for the authors’ observation;
or example, immunohistochemical staining for 2-
ubunits in vessel segments obtained at the time of
ascular surgery. Such studies would also be useful in
onfirming the authors’ observation of regional differ-
nces in uptake, with the descending aorta giving the
reatest signal and the carotid arteries the least.
Of most interest, but in need of confirmation in
his small study, is the finding that in the patients
ith PD or multiple system atrophy, a reduction in
he probe signal was observed in the ascending aorta
nd aortic arch (but not in the descending aorta or
arotid arteries) compared with the normal subjects
20). This finding mirrors the reduction in neuronal
42 receptors in the brains of these patients. Because
of the small numbers of patients, this finding may be
spurious. However, if confirmed, it is possible that the
nAChR expression in the proximal aorta mirrors that
in the brain. It is intriguing to speculate that this
regional difference in vascular nAChR expression
might be due to the fact that the proximal aorta isThe investigators note that further development
of the nAChR imaging technique will be useful in
exploring the role of nAChRs in vascular disease
(20). For example, it will be interesting to know, in
light of the earlier discussion, if exposure to tobacco
smoke alters the density of vascular nAChRs, and if
there is any regionality in this effect that might
explain the location of disease or its progression.
This is particularly relevant in light of recent
genomic evidence indicating that genetic variation
in nAChRs is associated with increased risk of
peripheral arterial disease (25). It is possible that
this genetic variation affects the responsiveness of
vascular (as well as neuronal) nAChRs to nicotine
in a manner that accelerates atherosclerosis.
Several deficiencies of the PET methods are
obvious. The technology has low spatial resolution,
and it is difficult to determine from the images
whether the intima, media, and/or adventitia are
generating the signal. Furthermore, this technology
in its current form cannot specify which cell types in
the vessel wall (endothelial, vascular smooth muscle,
fibroblasts, and/or immune cells) are providing the
signal. In addition, it is not clear how specific the
probe is for the 2 subunit and whether it may
be cross-reacting with other nAChR subtypes in the
vessel wall (e.g., the endothelial 7 homomer). The
echnology needs further testing and development to
efine its application as a clinical research tool.
Nevertheless, this paper (20) represents a first
tep toward using PET imaging to gain new in-
ights into the expression of vascular nAChRs in
ealth and disease. This is an important develop-
ent, as there is accumulating evidence that non-
euronal nAChRs play a significant role in the
egulation of vascular response. Our ability to image
hese peripheral nAChRs will lead to new under-
tandings of the function of the nicotinic cholin-
rgic pathway in vascular homeostasis and vascular
isease.
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